Integrating new AI screening tools for BRCA and HRD breast-cancer mutations into routine care could lead to earlier detection, more precise treatment, and lives saved. If they are aware of the threat, ...
As part of the ACLU's Taking Back Our Genes campaign , guest blogger Sue Friedman, the Executive Director of FORCE, describes the adverse impact the exclusive patents on BRCA1 and BRCA2 have on the ...
An affordable new BRCA gene test has hit the market, but who should take it? — -- A new genetic testing kit that hits the market today is the most affordable, and arguably one of the simplest, ...
Over 20% of high-grade serous ovarian cancer patients have BRCA mutations, and up to 50% exhibit HRD, impacting DNA repair pathways. Global guidelines recommend BRCA and HRD testing, but many eligible ...
Only 23.3% of ovarian cancer patients receive BRCA testing, leading to higher treatment costs and advanced therapy lines. Non-White and low-income patients face increased financial toxicity, ...
Last month, University College London Hospitals announced a new test for women at high risk of ovarian cancer due to inherited BRCA1 or BRCA2 gene mutations, who wish to defer preventative surgery. Dr ...
AI biotech company Owkin announced a partnership with pharma giant AstraZeneca to develop an AI-powered tool designed to prescreen for gBRCA mutations (gBRCAm) in breast cancer directly from digitized ...
Timely next-generation sequencing testing in patients with metastatic prostate cancer: A comparative analysis between Medicare Advantage and traditional Medicare. This is an ASCO Meeting Abstract from ...
You might hear about your risk of ovarian cancer through an aunt, mother, sister or grandmother. For some, there are no signs of hereditary cancer in the family, but genetic testing still reveals a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback